Do beta-blockers still have a place?;Is er nog plaats voor bètablokkers?

Tijdschrift voor Geneeskunde

Volumn 63, Issue 8, 2007, Pages 342-346

  Van Bortel, L ^a,b  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; SHORT ACTING DRUG;

FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; REVIEW; WORLD HEALTH ORGANIZATION;

EID: 34248147184     PISSN: 0371683X     EISSN: None     Source Type: Journal    
DOI: 10.2143/TVG.63.08.2000065     Document Type: Review

References (46)

1. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.
2. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-2007.
3. PACKER M, FOWLER MB, ROECKER EB, et al. Effect of Carvedilol on the morbidity of patients with severe chronic heart failure: results from the Carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002; 106: 2194-2199.
4. FLATHER MD, SHIBATA MC, COATS AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215-225.
5. TANG W, MILITELLO M, FRANCIS GS. In heart failure, all beta-blockers are not necessarily equal. Cleve Clin J Med 2003; 70: 1081-1087.
6. WILLENHEIMER R, VAN VELDHUISEN DJ, SILKE B, et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. CIBIS III Investigators. Circulation 2005; 112: 2426-2435.
7. POOLE-WILSON PA, SWEDBERG K, CLELAND JG, et al. Comparison of Carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003; 362: 7-13.
8. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001; 344: 16591667.
9. YUSUF S, PETO R, LEWIS J, COLLINS R, SLEIGHT P. Beta-blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335-371.
10. DAHLOF B, DEVEREUX RB, KJELDSEN SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
11. DAHLOF B, SEVER PS, POULTER NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. ASCOT Investigators. Lancet 2005; 366: 895-906.
12. CARLBERG B, SAMUELSSON O, LINDHOLM LH. Atenolol in hypertension: is it a wise choice? Lancet 2004; 364: 1684-1689.
13. LINDHOLM LH, CARLBERG B, SAMUELSSON O. Should betablockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545-1553.
14. SEVER P. New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society. J Renin Angiotensin Aldosterone Syst 2006; 7: 61-63.
15. NEUTEL JM, SCHNAPER H, CHEUNG DG, GREATTINGER WF, WEBER MA. Antihypertensive effects of beta-blockers administered once daily: 24-hour measurements. Am Heart J 1990; 120: 166-171.
16. STAESSEN JA, WANG JG, THIJS L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003; 21: 1055-1076.
17. BROWN MJ, PALMER CR, CASTAIGNE A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000; 356: 366-372.
18. JULIUS S, KJELDSEN SE, WEBER M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. VALUE Trial Group. Lancet 2004; 363: 2022-2031.
19. REEVES RA, BOER WH, DELEVE L, LEENEN FH. Beta-blockade disappearance rate predicts beta-adrenergic hypersensitivity. Clin Pharmacol Ther 1989; 46: 279-290
20. KRUKEMYER JJ, BOUDOULAS H, BINKLEY PF, LIMA JJ. Comparison of hypersensitivity to adrenergic stimulation after abrupt withdrawal of propranolol and nadolol: influence of half-life differences. Am Heart J 1990; 120: 572-579.
21. FRISHMAN WH, ALWARSHETTY M. Beta-adrenergic blockers in systemic hypertension. pharmacokinetic considerations related to the current guidelines. Clin Pharmacokinet 2002; 41: 505-516.
22. KHAN N, MCALISTER FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ 2006; 174: 1737-1742.
23. GILES TD. Antihypertensive therapy and cardiovascular risk. Are all antihypertensives equal? Hypertension 1992; 19 (1 Suppl): I124-I129.
24. STEINER SS, FRIEDHOFF AJ, WILSON BL, WECKER JR, SANTO JP. Antihypertensive therapy and quality of life: a comparison of atenolol, Captopril, enalapril and propranolol. J Hum Hypertens 1990; 4: 217-225.
25. BREED JG, CIAMPRICOTTI R, TROMP GP, VALSTER FA, LAGERWEG E, VAN BORTEL LM. Quality of life perception during antihypertensive treatment, a comparative study of bisoprolol and enalapril. J Cardiovasc Pharmacol 1992; 20: 750-755.
26. DE HOON JN, VANMOLKOT FH, VAN DE VEN LL, VAN BORTEL LM. Quality of life between bisoprolol and nifedipine retard in hypertension. Cardiovasc Drugs Ther 1997; 11: 465-471.
27. VANMOLKOT FH, DE HOON JN, VAN DE VEN LL, VAN BORTEL LM. Impact of antihypertensive treatment on quality of life: comparison between bisoprolol and bendrofluazide. J Hum Hypertens 1999; 13: 559-563.
28. VAN BORTEL LM, VAN BAAK MA. Exercise tolerance with nebivolol and atenolol. Cardiovasc Drugs Ther 1992; 6: 239-247.
29. CLEOPHAS T. Experimental evidence on selective antagonistic action of nebivolol on beta-1-adrenergic receptors. J Clin Med 1998; 2: 2-8.
30. SCHNABEL P, MAACK C, MIES F, TYROLLER S, SCHEER A, BOHM M. Binding properties of beta-blockers at recombinant beta1-, beta2-, and beta3-adrenoceptors. J Cardiovasc Pharmacol 2000; 36: 466-471.
31. FOGARI R, ZOPPI A, CORRADI L, et al. Beta-blocker effects on plasma lipids during prolonged treatment of hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 1999; 33: 534-539.
32. VAN BORTEL LM, BREED JG, JOOSTEN J, KRAGTEN JA, LUSTERMANS FA, MOOIJ JM. Nebivolol in hypertension: a double blind placebo-controlled multicenter study assessing its antihypertensive efficacy and impact on quality of life. J Cardiovasc Pharmacol 1993; 21: 856-862.
33. NUTTALL SL, ROUTLEDGE HC, KENDALL MJ. A comparison of the beta1-selectivity of three beta1-selective beta-blockers. J Clin Pharm Ther 2003; 28: 179-186.
34. FOGARI R, ZOPPI A, LAZZARI P, et al. Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes. J Hum Hypertens 1997; 11: 753-757.
35. BARZILAY JI, DAVIS BR, CUTLER JA, et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Collaborative Research Group. Arch Intern Med 2006; 166: 2191-2201.
36. MANCIA G, GRASSI G, ZANCHETTI A. New-onset diabetes and antihypertensive drugs. J Hypertens 2006; 24: 3-10.
37. WEBBER J, MACDONALD IA. Signalling in body-weight homeostasis: neuroendocrine efferent signals. Proc Nutr Soc 2000; 59: 397-404.
38. CELIK T, IYISOY A, KURSAKLIOGLU H, et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 2006; 24: 591-596.
39. MALMINIEMI K, LAHTELA J, MALMINIEMI O, ALA-KAILA K, HUUPPONEN R. Insulin sensitivity in a long-term crossover trial with celiprolol and other antihypertensive agents. J Cardiovasc Pharmacol 1998; 31: 140-145.
40. TZEMOS N, LIM PO, MACDONALD TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation 2001; 104: 511-514.
41. VAN BORTEL LM, DE HOON JN, KOOL MJ, WIJNEN JA, VERTOMMEN CI, VAN NUETEN LG. Pharmacological properties of nebivolol in man. Eur J Clin Pharmacol 1997; 51: 379-384.
42. VAN BORTEL LM, BULPITT CJ, FICI F. Quality of life and antihypertensive effect with nebivolol and losartan. Am J Hypertens 2005; 18: 1060-1066.
43. VAN BORTEL LM, WIJNEN JA, HARTGENS F, KUIPERS H, VAN BAAK MA. Effect of Carvedilol on endurance exercise performance. Eur Heart J 1995; 16 (abstract suppl): 60.
44. FOGARI R, ZOPPI A, POLETTI L, MARASI G, MUGELLINI A, CORRAOLI L. Sexual activity in hypertensive men treated with valsartan or Carvedilol: a crossover study. Am J Hypertens 2001; 14: 27-31.
45. BOUTOUYRIE P, BUSSY C, HAYOZ D, et al. Local pulse pressure and regression of arterial wall hypertrophy during long-term antihypertensive treatment. Circulation 2000; 101: 2601-2606.
46. WIKLUND O, HULTHE J, WIKSTRAND J, SCHMIDT C, OLOFSSON SO, BONDJERS G. Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke 2002; 33: 572-577.